Hemophilia- MCQs Welcome to your Hemophilia- MCQs 1. Deficiency of which of the following factors is known as parahemoplilia? A. Factor V B. Factor VIII C. Factor VII D. Factor II 2. Which of the following is a new recombinant humanized IgG4 bispecific antibody used for the treatment of Hemophilia A A. Eculizumab B. Emicizumab C. Abciximab D. Daratumumumab 3. Which of the following is matched correctly? A. Adsorbed plasma - lacks factors II and VII B. Aged plasma -lacks factors II, VII, XI and X C. Serum - lacks factors I, V and VIII D. All are correctly matched 4. True regarding FVIII inhibitors is? A. 90 % of patients with hemophilia A develop persistent inhibitors to FVIII B. Mixing study with normal plasma when performed results in a delayed correction of APTT, if an inhibitor is present C. Diagnosis is confirmed by bethesda assay D. Inhibitor is present when bethesda assay shows levels > 1 BU/ml Time is Up! Time's up Share this:FacebookTelegramWhatsAppMoreLinkedInTwitterLike this:Like Loading...